Your shopping cart is currently empty

BNT411, a selective TLR7 agonist, induces IFNα release both in vivo and in vitro. With anticancer activity, BNT411 is applicable in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $5,640 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $8,410 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $10,790 | 6-8 weeks | 6-8 weeks |
| Description | BNT411, a selective TLR7 agonist, induces IFNα release both in vivo and in vitro. With anticancer activity, BNT411 is applicable in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1]. |
| In vivo | BNT411 (3 mg/kg; administered via intravenous injection every 4 to 5 days, for a total of 8 doses) demonstrates antitumor activity in a mouse tumor model [1]. |
| Molecular Weight | 439.55 |
| Formula | C24H33N5O3 |
| Cas No. | 2296821-50-4 |
| Smiles | C(CCCN(C(C)=O)C1CCOCC1)N2C=3C=4C(N=C(N)C3N=C2CCOC)=CC=CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.